The Report
Verified funding, headquarters, and leadership news from the world's most innovative businesses
205 reports and counting
CRISPR Therapeutics raises $337M Follow-on Offering at $8B valuation
CRISPR Therapeutics raises $337M in Follow-on Offering at $8B valuation. Gene-based medicines using CRISPR/Cas9...
CRISPR Therapeutics Raises $337M in Follow-on Offering
CRISPR Therapeutics, a Biotech company based in Aeschenvorstadt 36, Basel 4051, Switzerland, has raised $337M in Follow-on Offering at a $8B valuation led by Versant Ventures, Bayer, Vertex Pharmaceuticals.
Intellia Therapeutics raises $350M Follow-on Offering at $4.5B valuation
Intellia Therapeutics raises $350M in Follow-on Offering at $4.5B valuation. In vivo CRISPR gene editing...
Intellia Therapeutics Raises $350M in Follow-on Offering
Intellia Therapeutics, a Biotech company based in 40 Erie Street, Cambridge, MA 02139, has raised $350M in Follow-on Offering at a $4.5B valuation led by Atlas Venture, Novartis Venture Fund, Venrock, Lilly Asia Ventures.
Arnatar Therapeutics raises $52M Series A
Arnatar Therapeutics raises $52M in Series A. Developing therapeutics for autoimmune and inflammatory diseases...
Denali Therapeutics raises $217M Series C at $5B valuation
Denali Therapeutics raises $217M in Series C at $5B valuation. Neurodegeneration therapeutics...
Strand Therapeutics raises $153M Series B
Strand Therapeutics raises $153M in Series B. mRNA-based therapeutics developer with novel cancer treatment platform...
Seres Therapeutics raises $113M Series E at $450M valuation
Seres Therapeutics raises $113M in Series E at $450M valuation. Microbiome therapeutic platform...
Crystalys Therapeutics raises $205M Series B at $900M valuation
Crystalys Therapeutics raises $205M in Series B at $900M valuation. Developing novel therapeutics for neurodegenerative diseases...
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.